Silence Therapeutics plc reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was GBP 3.64 million compared to GBP 2.7 million a year ago. Net loss was GBP 11.94 million compared to GBP 11.63 million a year ago. Basic loss per share from continuing operations was GBP 0.399 compared to GBP 0.393 a year ago.
For the six months, sales was GBP 9.37 million compared to GBP 5.85 million a year ago. Net loss was GBP 19.62 million compared to GBP 20.05 million a year ago. Basic loss per share from continuing operations was GBP 0.657 compared to GBP 0.684 a year ago.